Articles related to ASCO

ASCO GU 2024: Advances in Prostate Cancer

Recent studies highlight the potential of cabozantinib plus atezolizumab in improving progression-free survival for mCRPC patients and confirm the benefits of high-dose radiotherapy in high-risk prostate cancer treatment, offering new insights into personalized care strategies.

Medical Oncology February 20th 2024

Tags: ASCO GENITOURINARY CANCER PROSTATE CANCER

Cancer Therapy Advisor

ASCO GI 2024: Data May Change Practice in HCC

Recent findings from the ASCO Gastrointestinal Cancers Symposium 2024 underscore the potential of innovative therapeutic combinations in enhancing outcomes for hepatocellular carcinoma patients, particularly those with unresectable or high-risk disease.

Medical Oncology February 12th 2024

Tags: ASCO IMMUNOTHERAPY LIVER CANCER RADIOTHERAPY SURGICAL ONCOLOGY

Oncology News Central (ONC)

A Tale of Two ICIs: Adjuvant Pembro Ups Survival in RCC, Nivo Doesn’t

Pembrolizumab now represents a transformative advancement in the adjuvant treatment of clear cell renal cell carcinoma, significantly reducing the risk of progression or death by 38% compared to placebo.

Medical Oncology February 5th 2024

Tags: ADJUVANT TREATMENT ASCO CHECKPOINT INHIBITORS GENITOURINARY CANCER KIDNEY CANCER/RCC

<< 1 2 3

Trending Topics:

Articles related to ASCO

ASCO GU 2024: Advances in Prostate Cancer

ASCO GI 2024: Data May Change Practice in HCC

A Tale of Two ICIs: Adjuvant Pembro Ups Survival in RCC, Nivo Doesn’t

Topics

Sources

The Healthcare Communications Network is owned and operated by IQVIA Inc. Click below to leave this site and continue to IQVIA’s Privacy Choices form

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form